Leading Justice is a full-service marketing company working with law firms on a cash buy basis to sign up fully-qualified, fraud-free Invokana cases. Here at Leading Justice, we can custom-tailor your firm’s Invokana advertising needs and help you sign up cases via internal cash buys. Our clients only pay an agency fee to cover the cost of Invokana advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. In addition, we cross-qualify all of our contacts, meaning any data we generate that isn’t eligible for the target campaign is reviewed to determine whether it qualifies for another type of claim. By using state-of-the-art approaches to target contacts specifically related to Invokana use and side effects like lower limb amputations, Leading Justice will increase your firm’s Invokana case load. If you are interested in helping victims of alleged Invokana side effects, our vast consumer reach and direct advertising strategies at Leading Justice give you the competitive edge and confidence to allocate your full budget and rest easy knowing your money is being used in the best way possible.
Each law firm we work with at Leading Justice plays a critical role in how we classify claims as qualified or not. Our extensive experience working with plaintiff law firms helps us recognize a great case when we see one, but we will customize our Invokana case intake specifications to meet the exact criteria you are seeking. So, if your firm has specific Invokana qualifying case criteria you would like us to use, we can train our intake specialists to apply the criteria to each email and phone call they receive. By getting rid of the middle man, Leading Justice offers clients an opportunity for internal cash buys of Invokana data with no chance of fraud.
Invokana Side Effect Litigation
Invokana belongs to a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors, which are commonly prescribed in combination with diet and exercise to lower blood sugar levels in adults with Type 2 diabetes. However, serious concerns have been raised about the alleged risk of Invokana side effects, after an examination of adverse event reports submitted to the U.S. Food and Drug Administration (FDA) found a potential link between SGLT2 inhibitors and complications like lower limb amputations, ketoacidosis, kidney failure, diabetic coma and death. In two clinical trials (CANVAS and CANVAS-R) designed to assess cardiovascular risk in Type 2 diabetes patients taking Invokana, researchers found that, while the drug can help reduce heart problems in users, it nearly doubles the risk of lower extremity amputations.
Less than six months after the results from the CANVAS and CANVAS-R trials were released, an analysis of safety reports from the FDA’s adverse event reporting system indicated that, of 66 reports submitted in connection with the SGLT-2 inhibitor class of diabetes drugs, 57 (86%) involved Invokana. Although Invokana has been marketed by Johnson & Johnson and its Janssen Pharmaceuticals subsidiary as a safe and effective way to control blood sugar in Type 2 diabetes patients, mounting evidence suggests that Invokana and other SGLT2 inhibitors like Invokamet, Farxiga, Xigduo XR, Jardiance and Glyxambi may put users at risk for lower limb amputations, diabetic ketoacidosis, kidney failure, heart attack, stroke, diabetic coma, and other potentially life-threatening side effects.